ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK

Core Viewpoint - Rosen Law Firm is reminding purchasers of GSK plc American Depositary Receipts (ADRs) about a class action lawsuit related to misleading statements made by GSK regarding the withdrawal of Zantac from the market and its implications for investors [1][4][5]. Group 1: Class Action Details - The class action pertains to GSK ADRs purchased between February 5, 2020, and August 14, 2022, with a lead plaintiff deadline of April 7, 2025 [1][2]. - Investors who purchased GSK ADRs during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. Group 2: Allegations Against GSK - The complaint alleges that GSK misrepresented the reasons for withdrawing Zantac, claiming it was based on available information and regulatory correspondence, while in reality, GSK had known about the source of NDMA for nearly 40 years [4][5]. - GSK assured investors that there was no causal link between ranitidine therapy and cancer, which was later revealed to be misleading as they had concealed an internal study implicating their liability [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel, highlighting its track record in securities class actions and significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3].